Top

Published in:

Open Access 01-12-2019 | Pulmonary-Function Tests | Review

Role of medical and molecular imaging in COPD

Authors: Lukasz A. Myc, Yun M. Shim, Victor E. Laubach, Julien Dimastromatteo

Published in: Clinical and Translational Medicine | Issue 1/2019

Abstract

Chronic obstructive pulmonary disease (COPD) is expected to climb on the podium of the leading causes of mortality worldwide in the upcoming decade. Clinical diagnosis of COPD has classically relied upon detecting irreversible airflow obstruction on pulmonary function testing as a global assessment of pulmonary physiology. However, the outcome is still not favorable to decrease mortality due to COPD. Progress made in both medical and molecular imaging fields are beginning to offer additional tools to address this clinical problem. This review aims to describe medical and molecular imaging modalities used to diagnose COPD and to select patients for appropriate treatments and to monitor response to therapy.

Mannino DM, Buist AS (2007) Global burden of COPD: risk factors, prevalence, and future trends. Lancet 370(9589):765–773CrossRef

McDonough JE, Yuan R, Suzuki M, Seyednejad N, Elliott WM, Sanchez PG et al (2011) Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med 365(17):1567–1575CrossRef

Han MK, Kazerooni EA, Lynch DA, Liu LX, Murray S, Curtis JL et al (2011) Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology 261(1):274–282CrossRef

Aaron CP, Schwartz JE, Hoffman EA, Angelini E, Austin JHM, Cushman M et al (2018) A longitudinal cohort study of aspirin use and progression of emphysema-like lung characteristics on ct imaging: the MESA Lung Study. Chest 154(1):41–50CrossRef

Iyer AS, Wells JM, Vishin S, Bhatt SP, Wille KM, Dransfield MT (2014) CT scan-measured pulmonary artery to aorta ratio and echocardiography for detecting pulmonary hypertension in severe COPD. Chest 145(4):824–832CrossRef

Hueper K, Vogel-Claussen J, Parikh MA, Austin JH, Bluemke DA, Carr J et al (2015) Pulmonary microvascular blood flow in mild chronic obstructive pulmonary disease and emphysema. The MESA COPD Study. Am J Respir Crit Care Med 192(5):570–580CrossRef

Nakano Y, Muro S, Sakai H, Hirai T, Chin K, Tsukino M et al (2000) Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function. Am J Respir Crit Care Med 162(3 Pt 1):1102–1108CrossRef

Bushberg JT, Seibert JA, Leidholdt EM, Boone JM, Mahesh M (2013) The essential physics of medical imaging, third edition. Med Phys 40(7):077301CrossRef

Ostridge K, Williams NP, Kim V, Harden S, Bourne S, Clarke SC et al (2018) Relationship of CT-quantified emphysema, small airways disease and bronchial wall dimensions with physiological, inflammatory and infective measures in COPD. Respir Res 19(1):31CrossRef

10.

Hoffman EA, Lynch DA, Barr RG, van Beek EJ, Parraga G, Investigators I (2016) Pulmonary CT and MRI phenotypes that help explain chronic pulmonary obstruction disease pathophysiology and outcomes. J Magn Reson Imaging 43(3):544–557CrossRef

11.

Alford SK, van Beek EJR, McLennan G, Hoffman EA (2010) Heterogeneity of pulmonary perfusion as a mechanistic image-based phenotype in emphysema susceptible smokers. Proc Natl Acad Sci U S A 107(16):7485–7490CrossRef

12.

Estepar RS, Kinney GL, Black-Shinn JL, Bowler RP, Kindlmann GL, Ross JC et al (2013) Computed tomographic measures of pulmonary vascular morphology in smokers and their clinical implications. Am J Respir Crit Care Med 188(2):231–239CrossRef

13.

Pike D, Kirby M, Guo F, McCormack DG, Parraga G (2015) Ventilation heterogeneity in ex-smokers without airflow limitation. Acad Radiol 22(8):1068–1078CrossRef

14.

van Beek EJR, Dahmen AM, Stavngaard T, Gast KK, Heussel CP, Krummenauer F et al (2009) Hyperpolarised 3He MRI versus HRCT in COPD and normal volunteers: PHIL trial. Eur Respir J 34(6):1311–1321CrossRef

15.

Mugler JP, Altes TA, Ruset IC, Dregely IM, Mata JF, Miller GW et al (2010) Simultaneous magnetic resonance imaging of ventilation distribution and gas uptake in the human lung using hyperpolarized xenon-129. Proc Natl Acad Sci U S A 107(50):21707–21712CrossRef

16.

Qing K, Shim YM, Tustison NJ, Altes TA, Ruppert K, Mata JF, et al. Hyperpolarized xenon-129 MRI: a new tool to evaluate COPD. American Thoracic Society; 2016; p A1049

17.

Ohno Y, Hatabu H (2007) Basics concepts and clinical applications of oxygen-enhanced MR imaging. Eur J Radiol 64(3):320–328CrossRef

18.

Fuseya Y, Muro S, Sato S, Tanabe N, Sato A, Tanimura K et al (2018) Complementary regional heterogeneity information from COPD patients obtained using oxygen-enhanced MRI and chest CT. PLoS ONE 13(8):e0203273CrossRef

19.

Izquierdo-Alonso JL, Rodriguez-Gonzálezmoro JM, de Lucas-Ramos P, Unzueta I, Ribera X, Antón E et al (2013) Prevalence and characteristics of three clinical phenotypes of chronic obstructive pulmonary disease (COPD). Respir Med 107(5):724–731CrossRef

20.

Márquez-Martín E, Ramos PC, López-Campos JL, del Serrano Gotarredona M P, Herrero SN, Aguilar RT et al (2011) Components of physical capacity in patients with chronic obstructive pulmonary disease: relationship with phenotypic expression. Int J Chron Obstruct Pulmon Dis 6:105–112CrossRef

21.

Paige M, Burdick MD, Kim S, Xu J, Lee JK, Shim YM (2011) Pilot analysis of the plasma metabolite profiles associated with emphysematous Chronic Obstructive Pulmonary Disease phenotype. Biochem Biophys Res Commun 413(4):588–593CrossRef

22.

Carolan BJ, Hughes G, Morrow J, Hersh CP, O’Neal WK, Rennard S et al (2014) The association of plasma biomarkers with computed tomography-assessed emphysema phenotypes. Respir Res 15:127CrossRef

23.

Nakamura M, Nakamura H, Minematsu N, Chubachi S, Miyazaki M, Yoshida S et al (2014) Plasma cytokine profiles related to smoking-sensitivity and phenotypes of chronic obstructive pulmonary disease. Biomarkers 19(5):368–377CrossRef

24.

Golpe R, Sanjuán López P, Cano Jiménez E, Castro Añón O, Pérez de Llano LA (2014) Distribution of clinical phenotypes in patients with chronic obstructive pulmonary disease caused by biomass and tobacco smoke. Arch Bronconeumol 50(8):318–324CrossRef

25.

Kim V, Davey A, Comellas AP, Han MK, Washko G, Martinez CH et al (2014) Clinical and computed tomographic predictors of chronic bronchitis in COPD: a cross sectional analysis of the COPDGene study. Respir Res 15:52CrossRef

26.

Jones H (2002) Kinetics of lung macrophages monitored in vivo following particulate challenge in rabbits. Toxicol Appl Pharmacol 183(1):46–54CrossRef

27.

Jones HA, Marino PS, Shakur BH, Morrell NW (2003) In vivo assessment of lung inflammatory cell activity in patients with COPD and asthma. Eur Respir J 21(4):567–573CrossRef

28.

Subramanian DR, Jenkins L, Edgar R, Quraishi N, Stockley RA, Parr DG (2012) Assessment of pulmonary neutrophilic inflammation in emphysema by quantitative positron emission tomography. Am J Respir Crit Care Med 186(11):1125–1132CrossRef

29.

Faner R, Cruz T, Agustí A (2013) Immune response in chronic obstructive pulmonary disease. Expert Rev Clin Immunol. 9(9):821–833CrossRef

30.

Jörgensen K, Müller MF, Nel J, Upton RN, Houltz E, Ricksten S-E (2007) Reduced intrathoracic blood volume and left and right ventricular dimensions in patients with severe emphysema: an MRI study. Chest 131(4):1050–1057CrossRef

31.

Jögi J, Ekberg M, Jonson B, Bozovic G, Bajc M (2011) Ventilation/perfusion SPECT in chronic obstructive pulmonary disease: an evaluation by reference to symptoms, spirometric lung function and emphysema, as assessed with HRCT. Eur J Nucl Med Mol Imaging 38(7):1344–1352CrossRef

32.

Golestani R, Razavian M, Ye Y, Zhang J, Jung J-J, Toczek J et al (2017) Matrix metalloproteinase-targeted imaging of lung inflammation and remodeling. J Nucl Med 58(1):138–143CrossRef

33.

Li W, Li J, Wu Y, Wu J, Hotchandani R, Cunningham K et al (2009) A selective matrix metalloprotease 12 inhibitor for potential treatment of chronic obstructive pulmonary disease (COPD): discovery of (S)-2-(8-(methoxycarbonylamino)dibenzo[b, d]furan-3-sulfonamido)-3-methylbutanoic acid (MMP408). J Med Chem 52(7):1799–1802CrossRef

34.

Kondo N, Temma T, Aita K, Shimochi S, Koshino K, Senda M et al (2018) Development of matrix metalloproteinase-targeted probes for lung inflammation detection with positron emission tomography. Sci Rep 8(1):1347CrossRef

35.

Esteban C, Quintana JM, Moraza J, Aburto M, Aguirre U, Aguirregomoscorta JI et al (2010) BODE-Index vs HADO-score in chronic obstructive pulmonary disease: which one to use in general practice? BMC Med 8:28CrossRef

36.

Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA et al (2004) The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350(10):1005–1012CrossRef

37.

Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P et al (2007) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 176(6):532–555CrossRef

38.

Gold Reports 2018 [Internet]. Global initiative for chronic obstructive lung disease—GOLD. https://goldcopd.org/gold-reports/. Accessed 16 Oct 2018

39.

Wells JM, Washko GR, Han MK, Abbas N, Nath H, Mamary AJ et al (2012) Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med 367(10):913–921CrossRef

40.

Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R et al (2010) Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363(12):1128–1138CrossRef

41.

Johannessen A, Skorge TD, Bottai M, Grydeland TB, Nilsen RM, Coxson H et al (2013) Mortality by level of emphysema and airway wall thickness. Am J Respir Crit Care Med 187(6):602–608CrossRef

42.

Lynch DA, Moore CM, Wilson C, Nevrekar D, Jennermann T, Humphries SM et al (2018) CT-based visual classification of emphysema: association with mortality in the COPD Gene Study. Radiology 288:859–866CrossRef

43.

Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A et al (2003) A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 348(21):2059–2073CrossRef

44.

Sciurba FC, Ernst A, Herth FJ, Strange C, Criner GJ, Marquette CH et al (2010) A randomized study of endobronchial valves for advanced emphysema. N Engl J Med 363(13):1233–1244CrossRef

45.

Kim V, Desai P, Newell JD, Make BJ, Washko GR, Silverman EK et al (2014) Airway wall thickness is increased in COPD patients with bronchodilator responsiveness. Respir Res 15:84CrossRef

46.

De Luca N, Capuzi P, D’Angeli AL, D’Antoni L, Pavone P, De Santis M et al (1999) High resolution computed tomography (HRCT) assessment of beta 2-agonist induced bronchodilation in chronic obstructive pulmonary disease patients. Eur Rev Med Pharmacol Sci 3(2):83–87PubMed

47.

Kirby M, Mathew L, Heydarian M, Etemad-Rezai R, McCormack DG, Parraga G (2011) Chronic obstructive pulmonary disease: quantification of bronchodilator effects by using hyperpolarized (3)He MR imaging. Radiology 261(1):283–292CrossRef

48.

Iyer KS, Newell JD Jr, Jin D, Fuld MK, Saha PK, Hansdottir S et al (2016) Quantitative dual-energy computed tomography supports a vascular etiology of smoking-induced inflammatory lung disease. Am J Respir Crit Care Med 193(6):652–661CrossRef

49.

Lee SM, Kim SS, Hwang HJ, Seo JB. Imaging of COPD. In: COPD [Internet]. Berlin, Heidelberg: Springer Berlin Heidelberg; 2017. p 87–127CrossRef

50.

Chapman KR, Burdon JG, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM et al (2015) Intravenous augmentation treatment and lung density in severe alpha1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet 386(9991):360–368CrossRef

51.

Stockley RA, Parr DG, Piitulainen E, Stolk J, Stoel BC, Dirksen A (2010) Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res 11:136CrossRef

52.

Dimastromatteo J, Charles EJ, Laubach VE (2018) Molecular imaging of pulmonary diseases. Respir Res 19(1):17CrossRef

Title: Role of medical and molecular imaging in COPD
Authors: Lukasz A. Myc
Yun M. Shim
Victor E. Laubach
Julien Dimastromatteo
Publication date: 01-12-2019
Publisher: Springer Berlin Heidelberg
Keywords: Pulmonary-Function Tests
Computed Tomography
Computed Tomography
Molecular Imaging
Chronic Obstructive Lung Disease
Published in: Clinical and Translational Medicine / Issue 1/2019
Electronic ISSN: 2001-1326
DOI: https://doi.org/10.1186/s40169-019-0231-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Role of medical and molecular imaging in COPD

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

The dual functional role of MicroRNA-18a (miR-18a) in cancer development

Impact of fatty acid binding protein 5-deficiency on COPD exacerbations and cigarette smoke-induced inflammatory response to bacterial infection

Clinical features of Sjögren’s syndrome patients with autoantibodies against interferons

Circulating free DNA concentration as a marker of disease recurrence and metastatic potential in lung cancer

Circulating monocytes and tumor-associated macrophages express recombined immunoglobulins in glioblastoma patients

Sites of synchronous distant metastases and prognosis in prostate cancer patients with bone metastases at initial diagnosis: a population-based study of 16,643 patients